Literature DB >> 15699465

Role of Rho-kinase and p27 in angiotensin II-induced vascular injury.

Takeshi Kanda1, Koichi Hayashi, Shu Wakino, Koichiro Homma, Kyoko Yoshioka, Kazuhiro Hasegawa, Naoki Sugano, Satoru Tatematsu, Ichiro Takamatsu, Takayuki Mitsuhashi, Takao Saruta.   

Abstract

Angiotensin II enhances the development of atherosclerotic lesion in which cellular proliferation and/or migration are critical steps. Although cyclin-dependent kinase inhibitor, p27, and Rho/Rho-kinase pathway have recently been implicated as factors regulating these events cooperatively, their role in vivo has not been fully elucidated. We evaluated the contribution of p27 and Rho-kinase to angiotensin II-induced vascular injury using p27-deficient mice. Two-week angiotensin II (1500 ng/kg per minute SC) infusion elicited similar degrees of elevation in systolic blood pressure in wild-type mice (159+/-5 mm Hg) and p27-deficient mice (157+/-5 mm Hg; P>0.05). Angiotensin II infusion to wild-type mice resulted in increases in the medial thickness of aorta, proliferating cell number, and monocyte/macrophage infiltration within the vasculature. In p27-deficient mice, however, these changes were more prominent than those in wild-type mice. Treatment of wild-type mice with fasudil, a selective Rho-kinase inhibitor, did not alter blood pressure but significantly upregulated p27 expression, decreased medial thickness of aorta, reduced proliferating cell number, and prevented monocyte/macrophage infiltration. These protective effects of fasudil were attenuated in p27-deficient mice. In conclusion, p27 constitutes an important modulator of angiotensin II-induced monocyte/macrophage infiltration and vascular remodeling, which is mediated in part by Rho-kinase stimulation. Inhibition of Rho-kinase activity improves angiotensin II-induced vascular injury through p27-dependent and p27-independent mechanisms.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15699465     DOI: 10.1161/01.HYP.0000153316.59262.79

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  18 in total

Review 1.  The role of Rho protein signaling in hypertension.

Authors:  Gervaise Loirand; Pierre Pacaud
Journal:  Nat Rev Cardiol       Date:  2010-08-31       Impact factor: 32.419

Review 2.  Therapeutic potential of RhoA/Rho kinase inhibitors in pulmonary hypertension.

Authors:  M Oka; K A Fagan; P L Jones; I F McMurtry
Journal:  Br J Pharmacol       Date:  2008-06-09       Impact factor: 8.739

Review 3.  Involvement of Rho GTPases and their regulators in the pathogenesis of hypertension.

Authors:  Gervaise Loirand; Pierre Pacaud
Journal:  Small GTPases       Date:  2014-10-31

Review 4.  The COP9 signalosome and vascular function: intriguing possibilities?

Authors:  Douglas S Martin; Xuejun Wang
Journal:  Am J Cardiovasc Dis       Date:  2015-03-20

5.  The Rho GTPase effector ROCK regulates cyclin A, cyclin D1, and p27Kip1 levels by distinct mechanisms.

Authors:  Daniel R Croft; Michael F Olson
Journal:  Mol Cell Biol       Date:  2006-06       Impact factor: 4.272

Review 6.  Rho kinase inhibition in diabetic kidney disease.

Authors:  Radko Komers
Journal:  Br J Clin Pharmacol       Date:  2013-10       Impact factor: 4.335

7.  FP-receptor gene silencing ameliorates myocardial fibrosis and protects from diabetic cardiomyopathy.

Authors:  Wen-yuan Ding; Lin Liu; Zhi-hao Wang; Meng-xiong Tang; Yun Ti; Lu Han; Lei Zhang; Yun Zhang; Ming Zhong; Wei Zhang
Journal:  J Mol Med (Berl)       Date:  2014-02-07       Impact factor: 4.599

8.  28-Day hindlimb unweighting reduces expression of Rho kinase and inhibits its effects in femoral artery of rat.

Authors:  Zhong-Chao Wang; Huan Liu; Yun-Gang Bai; Jin-Wen Yu; Hai-Jun Zhang; Yao-Ping Cheng; Jun-Xiang Bao; Xin-Ling Ren; Hong-Zhe Ma; Jin Ma
Journal:  J Physiol Biochem       Date:  2015-03-12       Impact factor: 4.158

9.  Central role of Gq in the hypertrophic signal transduction of angiotensin II in vascular smooth muscle cells.

Authors:  Haruhiko Ohtsu; Sadaharu Higuchi; Heigoro Shirai; Kunie Eguchi; Hiroyuki Suzuki; Akinari Hinoki; Eugen Brailoiu; Andrea D Eckhart; Gerald D Frank; Satoru Eguchi
Journal:  Endocrinology       Date:  2008-03-20       Impact factor: 4.736

10.  Losartan counteracts the hyper-reactivity to angiotensin II and ROCK1 over-activation in aortas isolated from streptozotocin-injected diabetic rats.

Authors:  Paola Failli; Chiara Alfarano; Sergio Franchi-Micheli; Edoardo Mannucci; Elisabetta Cerbai; Alessandro Mugelli; Laura Raimondi
Journal:  Cardiovasc Diabetol       Date:  2009-06-22       Impact factor: 9.951

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.